Alzheimer's disease dementia
Conditions
Interventions
None listed
Sponsors
Vrije Universiteit Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Label of either subjective cognitive decline, Mild Cognitive Impairment or Alzheimer's Disease Signed informed consent projects P2005_160, P2000_211 (SCD: also SCIENCe P2014-019) Age * 50 years MMSE*19
Exclusion criteria
Exclusion criteria: Individuals who are considered medically unstable (assessed by physician) Insufficient knowledge of Dutch language Major psychiatric disorder, such as psychosis, schizophrenia, severe personality disorder or depression with vital signs, abuse of alcohol or other substances Neurological disorder such as Parkinson*s disease, symptomatic stroke, mental retardation Having a history of other neurological disorders known to influence smell and/or taste Acquired Immune Deficiency Syndrome (AIDS) or Human Immunodeficiency Virus (HIV) Having a severe food allergy Having a severe disease of the digestive tract, such as celiac disease, Crohn*s disease, active ulcerative colitis, short bowel syndrome Having a severe metabolic disorder, such as phenyl ketonuria A recent diagnosis of cancer or being actively treated for cancer (excluding basal cell carcinoma of the skin) Having a current upper respiratory infection or severe COPD (known GOLD 3 or 4) Being a regular smoker In MCI and AD patients: unavailability of a study partner to assist with the participation of NUDAD-L in patients with dementia
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Nutritional intake in patients with AD, in comparison with subjects with subjective cognitive decline or MCI. | — |
Secondary
| Measure | Time frame |
|---|---|
| Determining changed energy needs and body composition in patients with (pre-dementia) AD compared to healthy people and patients with advanced AD. Identifing altered eating behaviour in terms of olfactory and gustatory functioning, food preferences and satiety as determinants of altered food intake in patients with (pre-dementia) AD compared to healthy people and patients with advanced AD. Establishing relationships between nutritional intake and energy needs & body composition, and nutritional biomarkers. Pospectively validating panel of nutritional markers and relate them to measures of nutritional intake, energy requirements and body composition. Relating these markers to in*vivo measures of AD pathology (i.e. MRI, CSF biomarkers for AD, APOE status, EEG). | — |
Countries
Netherlands
Outcome results
None listed